Appendix Table 1.

Prevalence of elevated ASCVD risk in US Adults, aged 30–49 by risk factors; including participants on lipid-lowering medications: NHANES 1999 – 2012 (n=9,859)

Age group (years)	Male			Female
	Smokers	Non-smokers, Hypertension	Non-smokers, No Hypertension	Smokers	Non-smokers, Hypertension	Non-smokers, No Hypertension
30–34	9.3% (6.3%–13.5%)	2.8% (0.6%–11.7%)	0.0% (0.0%–0.5%*)	19.5% (14.0%–26.5%)	0.0% (0.0%–0.4%*)	0.0% (0.0%–0.4%*)
35–39	26.4% (21.9%–31.4%)	2.4% (1.3%–4.5%)	0.2% (0.1%–0.7%)	14.8% (11.0%–19.6%)	0.7% (0.2%–2.7%)	0.1% (0.0%–1.0%)
40–44	54.5%0 (48.1%–59.8%)	8.9% (5.7%–13.5%)	1.2% (0.4%–3.1%)	14.1% (9.8%–19.8%)	1.8% (0.8%–3.8%)	0.0% (0.0%–0.5%*)
45–49	76.9% (70.2%–82.4%)	30.3% (24.0%–37.5%)	6.0% (3.9%–9.2%)	19.3% (14.5%–25.3%)	4.9% (2.4%–9.6%)	0.3% (0.0%–1.8%)

^#Using 2013 ACC/AHA Pooled Cohort Equations ASCVD risk calculator.

^*Confidence intervals estimated using exact binomial methods.

Brackets show 95% confidence intervals for that subgroup.

Shaded cells represent low prevalence subgroups.